https://www.prnewswire.com/news-releases/gemmabio-unveils-duchenne-muscular-dystrophy-dmd-program-and-presents-preclinical-data-for-nextgeneration-gene-therapies-for-dmd-and-spinal-muscular-atrophy-type-1-sma1-at-the-asgct-2026-annual-meeting-302771279.html